产品名称	Patritumab (anti-ERBB3), 受体酪氨酸蛋白激酶 erbB-3 抑制剂
别名	帕曲妥单抗 \| 帕妥珠单抗（抗ERBB3）
英文别名	Anti-ERBB3 / HER3 Reference Antibody (patritumab) \| Patritumab \| Human Anti-ERBB3 Recombinant Antibody \| c erbB 3 antibody \| c erbB3 antibody \| Erb b2 receptor tyrosine kinase 3 antibody \| ErbB 3 antibody \| ERBB3 antibody \| ERBB3 protein antibody \| erbB3
规格或纯度	无载体, 重组, ExactAb™, 低内毒素, 无叠氮钠, 已验证, 无动物源, ≥95%(SDS-PAGE&SEC-HPLC), 见COA
宿主种属	人(Human)
特异性	ERBB3
应用	ELISA,Functional Assay,Kinetics (BLI),Kinetics (SPR),Flow Cyt
种属反应性	人(Human),大鼠(Rat)
偶联	Unconjugated
作用类型	抑制剂
作用机制	受体酪氨酸蛋白激酶 erbB-3 抑制剂

产品属性

抗体类型	Primary antibody
克隆类型	重组抗体
Format	Whole IgG
亚型	Human IgG1
轻链亚型	kappa
SDS-PAGE	28.0 kDa (Light Chain) & 51.9 kDa (Heavy Chain), under reducing conditions; 175.6 kDa, under non-reducing conditions.
纯化方法	Protein A purified
纯度	>95%
来源	CHO supernatant
物理外观	Liquid
储存缓冲液	Supplied as a 0.22 μm filtered solution in 100mM Pro-Ac, 20mM Arg, pH 5.0
防腐剂	No
浓度	见COA
储存温度	-80℃储存,避免反复冻融
运输条件	超低温冰袋运输
稳定性与储存	在 -80℃ 下保存 24 个月。收货后建议分装。避免冷冻/解冻循环。
CAS编号和信息	1262787-83-6
分子类型	抗体

图片

Flow Cytometry: Patritumab (anti-ERBB3) (Ab170705)

Patritumab (anti-ERBB3) (Ab170705) - Flow Cytometry
Flow Cytometry analysis of MCF-7 cells labelling ERBB3 (red) with Patritumab (anti-ERBB3) (Ab170705). Goat Anti-Human IgG (PE) (Ab175838) at a dilution of 1/1000 was used as the secondary antibody. Blue - Isotype control, human IgG (Ab170213). Black - Unlabelled control, cells without incubation with primary antibody.

SEC: Patritumab (anti-ERBB3) (Ab170705)

Patritumab (anti-ERBB3) (Ab170705) - SEC
The purity of Patritumab (anti-ERBB3) (Ab170705) is more than 95% verified by HPLC.

ELISA: Patritumab (anti-ERBB3) (Ab170705)

Patritumab (anti-ERBB3) (Ab170705) - ELISA
Immobilized Recombinant Human ErbB3 / HER3 protein (rp170123) at 1.0 μg/mL can bind Patritumab (anti-ERBB3) (Ab170705) with the EC₅₀ of 27.08 ng/mL.

关联靶点（人）

ERBB3 Tclin 受体酪氨酸蛋白激酶 erbB-3(Receptor tyrosine-protein kinase erbB-3) (0 活性数据)

点击查看靶蛋白信息： ERBB3

活性类型	活性值-log(M)	作用机制	期刊	参考文献(PubMed IDs)

作用机制

作用机制	Action Type	target ID	Target Name	Target Type	Target Organism	Binding Site Name	参考文献

安全和危险性（GHS）

SDS英文版

质量标准

质量标准

质检证书（CoA,COO,BSE/TSE 和分析图谱)

C of A & Other Certificates(BSE/TSE, COO):

输入批号以搜索分析图谱:

通过匹配包装上的批号来查找并下载产品的 COA，每批产品都进行了严格的验证，您可放心使用！

找到1个结果

批号(Lot Number)	证书类型	日期	货号
ZJ23F0800939	分析证书	23-08-30	Ab170705

可替换产品

参考文献

1. Cho HS, Leahy DJ. (2002) Structure of the extracellular region of HER3 reveals an interdomain tether.. Science, 297 (5585): (1330-3). [PMID:12154198]
2. Shi F, Telesco SE, Liu Y, Radhakrishnan R, Lemmon MA. (2010) ErbB3/HER3 intracellular domain is competent to bind ATP and catalyze autophosphorylation.. Proc Natl Acad Sci USA, 107 (17): (7692-7). [PMID:20351256]
3. Barlaam B, Anderton J, Ballard P, Bradbury RH, Hennequin LF, Hickinson DM, Kettle JG, Kirk G, Klinowska T, Lambert-van der Brempt C et al.. (2013) Discovery of AZD8931, an Equipotent, Reversible Inhibitor of Signaling by EGFR, HER2, and HER3 Receptors.. ACS Med Chem Lett, 4 (8): (742-6). [PMID:24900741]
4. Lafleur K, Huang D, Zhou T, Caflisch A, Nevado C. (2009) Structure-based optimization of potent and selective inhibitors of the tyrosine kinase erythropoietin producing human hepatocellular carcinoma receptor B4 (EphB4).. J Med Chem, 52 (20): (6433-46). [PMID:19788238]
5. Fitzgerald JB, Johnson BW, Baum J, Adams S, Iadevaia S, Tang J, Rimkunas V, Xu L, Kohli N, Rennard R et al.. (2014) MM-141, an IGF-IR- and ErbB3-directed bispecific antibody, overcomes network adaptations that limit activity of IGF-IR inhibitors.. Mol Cancer Ther, 13 (2): (410-25). [PMID:24282274]
6. McDonagh CF, Huhalov A, Harms BD, Adams S, Paragas V, Oyama S, Zhang B, Luus L, Overland R, Nguyen S et al.. (2012) Antitumor activity of a novel bispecific antibody that targets the ErbB2/ErbB3 oncogenic unit and inhibits heregulin-induced activation of ErbB3.. Mol Cancer Ther, 11 (3): (582-93). [PMID:22248472]
7. Lim SM, Xie T, Westover KD, Ficarro SB, Tae HS, Gurbani D, Sim T, Marto JA, Jänne PA, Crews CM et al.. (2015) Development of small molecules targeting the pseudokinase Her3.. Bioorg Med Chem Lett, 25 (16): (3382-9). [PMID:26094118]
8. Emily J Hanan,Charles Eigenbrot,Marian C Bryan,Daniel J Burdick,Bryan K Chan,Yuan Chen,Jennafer Dotson,Robert A Heald,Philip S Jackson,Hank La,Michael D Lainchbury,Shiva Malek,Hans E Purkey,Gabriele Schaefer,Stephen Schmidt,Eileen M Seward,Steve Sideris,Christine Tam,Shumei Wang,Siew Kuen Yeap,Ivana Yen,Jianping Yin,Christine Yu,Inna Zilberleyb,Timothy P Heffron. (2014-11-11) Discovery of selective and noncovalent diaminopyrimidine-based inhibitors of epidermal growth factor receptor containing the T790M resistance mutation.. Journal of medicinal chemistry, 57 ((23)): (10176-10191). [PMID:25383627]
9. Jang SW, Okada M, Sayeed I, Xiao G, Stein D, Jin P, Ye K.. (2007) Gambogic amide, a selective agonist for TrkA receptor that possesses robust neurotrophic activity, prevents neuronal cell death.. Proc Natl Acad Sci U S A, 104 (41): (16329-16334). [PMID:17911251] [10.1073/pnas.0706662104]
10. Ishikawa T, Seto M, Banno H, Kawakita Y, Oorui M, Taniguchi T, Ohta Y, Tamura T, Nakayama A, Miki H, Kamiguchi H, Tanaka T, Habuka N, Sogabe S, Yano J, Aertgeerts K, Kamiyama K.. (2011) Design and synthesis of novel human epidermal growth factor receptor 2 (HER2)/epidermal growth factor receptor (EGFR) dual inhibitors bearing a pyrrolo[3,2-d]pyrimidine scaffold.. J Med Chem, 54 (23): (8030-8050). [PMID:22003817] [10.1021/jm2008634]
11. Gonzalez-Lopez de Turiso F, Shin Y, Brown M, Cardozo M, Chen Y, Fong D, Hao X, He X, Henne K, Hu YL, Johnson MG, Kohn T, Lohman J, McBride HJ, McGee LR, Medina JC, Metz D, Miner K, Mohn D, Pattaropong V, Seganish J, Simard JL, Wannberg S, Whittington DA, Yu G, Cushing TD.. (2012) Discovery and in vivo evaluation of dual PI3Kβ/δ inhibitors.. J Med Chem, 55 (17): (7667-7685). [PMID:22876881] [10.1021/jm300679u]
12. Qin M, Wang T, Xu B, Ma Z, Jiang N, Xie H, Gong P, Zhao Y.. (2015) Novel hydrazone moiety-bearing aminopyrimidines as selective inhibitors of epidermal growth factor receptor T790M mutant.. Eur J Med Chem, 104 (115-126). [PMID:26451770] [10.1016/j.ejmech.2015.09.031]
13. Li X, Wang A, Yu K, Qi Z, Chen C, Wang W, Hu C, Wu H, Wu J, Zhao Z, Liu J, Zou F, Wang L, Wang B, Wang W, Zhang S, Liu J, Liu Q.. (2015) Discovery of (R)-1-(3-(4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)-2-(dimethylamino)ethanone (CHMFL-FLT3-122) as a Potent and Orally Available FLT3 Kinase Inhibitor for FLT3-ITD Positive Acute Myeloid Leukemia.. J Med Chem, 58 (24): (9625-9638). [PMID:26630553] [10.1021/acs.jmedchem.5b01611]
14. Jung ME, Byun BJ, Kim HM, Lee JY, Park JH, Lee N, Son YH, Choi SU, Yang KM, Kim SJ, Lee K, Kim YC, Choi G.. (2016) Discovery of indirubin derivatives as new class of DRAK2 inhibitors from high throughput screening.. Bioorg Med Chem Lett, 26 (11): (2719-2723). [PMID:27106709] [10.1016/j.bmcl.2016.03.111]
15. Schroeder RL, Goyal N, Bratton M, Townley I, Pham NA, Tram P, Stone T, Geathers J, Nguyen K, Sridhar J.. (2016) Identification of quinones as novel PIM1 kinase inhibitors.. Bioorg Med Chem Lett, 26 (13): (3187-3191). [PMID:27173800] [10.1016/j.bmcl.2016.04.079]
16. Bharate SB, Kumar V, Jain SK, Mintoo MJ, Guru SK, Nuthakki VK, Sharma M, Bharate SS, Gandhi SG, Mondhe DM, Bhushan S, Vishwakarma RA.. (2018) Discovery and Preclinical Development of IIIM-290, an Orally Active Potent Cyclin-Dependent Kinase Inhibitor.. J Med Chem, 61 (4): (1664-1687). [PMID:29370702] [10.1021/acs.jmedchem.7b01765]
17. Zhang Y, Lv H, Luo L, Xu Y, Pan Y, Wang Y, Lin H, Xiong J, Guo P, Zhang J, Li X, Ye F.. (2018) Design, synthesis and pharmacological evaluation of N4,N6-disubstituted pyrimidine-4,6-diamine derivatives as potent EGFR inhibitors in non-small cell lung cancer.. Eur J Med Chem, 157 (1300-1325). [PMID:30195240] [10.1016/j.ejmech.2018.08.031]
18. Mansour TS, Pallepati RR, Basetti V.. (2020) Potent dual EGFR/Her4 tyrosine kinase inhibitors containing novel (1,2-dithiolan-4-yl)acetamides.. Bioorg Med Chem Lett, 30 (16): (127288-127288). [PMID:32631510] [10.1016/j.bmcl.2020.127288]
19. Singh SS, Mattheolabakis G, Gu X, Withers S, Dahal A, Jois S.. (2021) A grafted peptidomimetic for EGFR heterodimerization inhibition: Implications in NSCLC models.. Eur J Med Chem, 216 (113312-113312). [PMID:33667849] [10.1016/j.ejmech.2021.113312]
20. Plowman, G D GD and 6 more authors.. (1990) Molecular cloning and expression of an additional epidermal growth factor receptor-related gene.. Proceedings of the National Academy of Sciences of the United States of America, [PMID:2164210]
21. Kraus, M H MH, Issing, W W, Miki, T T, Popescu, N C NC and Aaronson, S A SA.. (1989) Isolation and characterization of ERBB3, a third member of the ERBB/epidermal growth factor receptor family: evidence for overexpression in a subset of human mammary tumors.. Proceedings of the National Academy of Sciences of the United States of America, [PMID:2687875]
22. Katoh, M M, Yazaki, Y Y, Sugimura, T T and Terada, M M.. (1993) c-erbB3 gene encodes secreted as well as transmembrane receptor tyrosine kinase.. Biochemical and biophysical research communications, (14): [PMID:7685162]
23. Fiddes, R J RJ and 6 more authors.. (1998) Analysis of Grb7 recruitment by heregulin-activated erbB receptors reveals a novel target selectivity for erbB3.. The Journal of biological chemistry, (27): [PMID:9516479]
24. Lessor, T J TJ and Hamburger, A W AW.. (2001) Regulation of the ErbB3 binding protein Ebp1 by protein kinase C.. Molecular and cellular endocrinology, (25): [PMID:11325528]
25. Li, Yongqing Y and 7 more authors.. (2003) Heregulin targets gamma-catenin to the nucleolus by a mechanism dependent on the DF3/MUC1 oncoprotein.. Molecular cancer research : MCR, [PMID:12939402]
26. Kinugasa, Yumi Y and 5 more authors.. (2004) Neuroglycan C, a novel member of the neuregulin family.. Biochemical and biophysical research communications, (3): [PMID:15358134]
27. Scherer, Steven E SE and 216 more authors.. (2006) The finished DNA sequence of human chromosome 12.. Nature, (16): [PMID:16541075]
28. Liu, Zhixue Z, Ahn, Jee-Yin JY, Liu, Xia X and Ye, Keqiang K.. (2006) Ebp1 isoforms distinctively regulate cell survival and differentiation.. Proceedings of the National Academy of Sciences of the United States of America, (18): [PMID:16832058]
29. Narkis, Ginat G and 5 more authors.. (2007) Lethal congenital contractural syndrome type 2 (LCCS2) is caused by a mutation in ERBB3 (Her3), a modulator of the phosphatidylinositol-3-kinase/Akt pathway.. American journal of human genetics, [PMID:17701904]
30. Jura, Natalia N, Shan, Yibing Y, Cao, Xiaoxian X, Shaw, David E DE and Kuriyan, John J.. (2009) Structural analysis of the catalytically inactive kinase domain of the human EGF receptor 3.. Proceedings of the National Academy of Sciences of the United States of America, (22): [PMID:20007378]
31. Ieguchi, Katsuaki K and 8 more authors.. (2010) Direct binding of the EGF-like domain of neuregulin-1 to integrins ({alpha}v{beta}3 and {alpha}6{beta}4) is involved in neuregulin-1/ErbB signaling.. The Journal of biological chemistry, (8): [PMID:20682778]
32. Mineev, K S KS and 5 more authors.. (2011) Spatial structure and dimer--monomer equilibrium of the ErbB3 transmembrane domain in DPC micelles.. Biochimica et biophysica acta, [PMID:21575594]
33. Braunstein, E M EM and 9 more authors.. (2016) A germline ERBB3 variant is a candidate for predisposition to erythroid MDS/erythroleukemia.. Leukemia, [PMID:27416908]
34. Le, Thuy-Linh and 36 more authors.. (2021) Dysregulation of the NRG1-ERBB pathway causes a developmental disorder with gastrointestinal dysmotility in humans.. The Journal of clinical investigation, (26): [PMID:33497358]

溶液计算器

摩尔浓度计算器

计算溶液所需的质量、体积或浓度。

质量

浓度

体积

分子量

g/mol

稀释计算器

计算配制储备溶液所需的稀释度。

浓度1（C1）

体积 1 (V1)

浓度 2 (C2)

体积 2 (V2)

复溶计算器

复溶计算器允许您快速计算试剂的体积，以复溶小瓶。只需输入试剂的质量和目标浓度，计算器将确定其余部分。

体积（添加到小瓶中）

质量（小瓶）

所需的复溶浓度

Patritumab (anti-ERBB3), 受体酪氨酸蛋白激酶 erbB-3 抑制剂

库存信息

库存信息

库存信息

库存信息

基本信息

产品属性

图片

关联靶点（人）

作用机制

安全和危险性（GHS）

质量标准

质检证书（CoA,COO,BSE/TSE 和分析图谱)

相关产品

可替换产品

参考文献

溶液计算器

摩尔浓度计算器

稀释计算器

复溶计算器